The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Alina Striha, A. John Ashcroft, Anna Hockaday, David A. Cairns, Karen Boardman, Gwen Jacques, Cathy Williams, John A. Snowden, Mamta Garg, Jamie Cavenagh, Kwee Yong, Mark T. Drayson, Roger Owen, Mark Cook, Gordon Cook

ABSTRACT

BACKGROUND: Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors and immunomodulatory drugs. Despite these options, almost all patients will relapse post first-line autologous stem cell transplantation (ASCT). First relapse management (second-line treatment) has evolved in recent years with an expanding portfolio of novel agents, driving response rates influencing the durability of response. A second ASCT, as part of relapsed disease management (salvage ASCT), has been shown to prolong the progression-free survival and overall survival following a proteasome inhibitor-containing re-induction regimen, in the Cancer Research UK-funded National Cancer Research Institute Myeloma X (Intensive) study. It is now recommended that salvage ASCT be considered for suitable patients by the International Myeloma Working Group and the National Institute for Health and Care Excellence NG35 guidance. METHODS/DESIGN: ACCoRd (Myeloma XII) is a UK-nationwide, individually randomised, multi-centre, multiple randomisation, open-label phase III trial with an initial single intervention registration phase aimed at relapsing MM patients who have received ASCT in first-line treatment. We will register 406 participants into the trial to allow 284 and 248 participants to be randomised at the first and second randomisations, respectively. All participants will receive re-induction therapy until maximal response (four to six cycles of ixazomib, thalidomide and dexamethasone). Participants who achieve at least stable disease will be randomised (1:1) to receive either ASCTCon, using high-dose melphalan, or ASCTAug, using high-dose melphalan with ixazomib. All participants achieving or maintaining a minimal response or better, following salvage ASCT, will undergo a second randomisation (1:1) to consolidation and maintenance or observation. Participants randomised to consolidation and maintenance will receive consolidation with two cycles of ixazomib, thalidomide and dexamethasone, and maintenance with ixazomib until disease progression. DISCUSSION: The question of how best to maximise the durability of response to salvage ASCT warrants clinical investigation. Given the expanding scope of oral therapeutic agents, patient engagement with long-term maintenance strategies is a real opportunity. This study will provide evidence to better define post-relapse treatment in MM. TRIAL REGISTRATION: ISRCTN, ISRCTN10038996 . Registered on 15 December 2016. More... »

PAGES

169

Journal

TITLE

Trials

ISSUE

1

VOLUME

19

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-018-2524-8

DOI

http://dx.doi.org/10.1186/s13063-018-2524-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101375562

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29514706


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Boron Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maintenance Chemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm, Residual", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Progression-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteasome Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation Conditioning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Autologous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Striha", 
        "givenName": "Alina", 
        "id": "sg:person.015350452375.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015350452375.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pinderfields Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415005.5", 
          "name": [
            "Department of Haematology, Pinderfields General Hospital, Wakefield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ashcroft", 
        "givenName": "A. John", 
        "id": "sg:person.0675442301.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675442301.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hockaday", 
        "givenName": "Anna", 
        "id": "sg:person.07771451501.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07771451501.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cairns", 
        "givenName": "David A.", 
        "id": "sg:person.01100525223.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100525223.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boardman", 
        "givenName": "Karen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacques", 
        "givenName": "Gwen", 
        "id": "sg:person.013760076760.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013760076760.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nottingham University Hospitals NHS Trust", 
          "id": "https://www.grid.ac/institutes/grid.240404.6", 
          "name": [
            "Centre for Clinical Haematology, Nottingham University Hospitals (City Campus), Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Williams", 
        "givenName": "Cathy", 
        "id": "sg:person.016555374462.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016555374462.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sheffield Teaching Hospitals NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Snowden", 
        "givenName": "John A.", 
        "id": "sg:person.012030144222.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012030144222.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leicester Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.419248.2", 
          "name": [
            "Leicester Royal Infirmary, Leicester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garg", 
        "givenName": "Mamta", 
        "id": "sg:person.0764445325.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764445325.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St Bartholomew's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416353.6", 
          "name": [
            "Department of Haematology, St Bartholomew\u2019s Hospital, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cavenagh", 
        "givenName": "Jamie", 
        "id": "sg:person.0751765342.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751765342.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.439749.4", 
          "name": [
            "Department of Haematology, University College Hospital, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yong", 
        "givenName": "Kwee", 
        "id": "sg:person.0707335607.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707335607.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.6572.6", 
          "name": [
            "Myeloma Clinical Trials Unit, University of Birmingham, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Drayson", 
        "givenName": "Mark T.", 
        "id": "sg:person.01164220446.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164220446.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St James's University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.443984.6", 
          "name": [
            "HMDS, St James\u2019s University Hospital, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Owen", 
        "givenName": "Roger", 
        "id": "sg:person.01157221563.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157221563.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Elizabeth Hospital Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.415490.d", 
          "name": [
            "Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cook", 
        "givenName": "Mark", 
        "id": "sg:person.01344072571.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344072571.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Leeds Institute of Cancer & Pathology, University of Leeds, St James\u2019s University Hospital, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cook", 
        "givenName": "Gordon", 
        "id": "sg:person.07624006200.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07624006200.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bmt.2015.83", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007789680", 
          "https://doi.org/10.1038/bmt.2015.83"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ott.s49187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011617405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1740774510369019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011719554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1740774510369019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011719554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.335", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011949021", 
          "https://doi.org/10.1038/leu.2013.335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.335", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011949021", 
          "https://doi.org/10.1038/leu.2013.335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71125-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012022447"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.4780110205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012639418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bcj.2014.71", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013760776", 
          "https://doi.org/10.1038/bcj.2014.71"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428194.2012.746682", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015826881"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.12513", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016883864"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.39.6820", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029641259"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.leukres.2007.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033675460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2015.175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035017085", 
          "https://doi.org/10.1038/bmt.2015.175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1516282", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035239228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2015.356", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035584393", 
          "https://doi.org/10.1038/leu.2015.356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.61.2267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038717218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-01-548826", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039247879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2011-02-338665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042868402"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa022340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043734366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2009-06-229658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048946419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-06-1768", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049049948"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70245-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050595830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2352-3026(16)30049-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051977126"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2530245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069975779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2988298", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1102979429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2988298", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1102979429"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors and immunomodulatory drugs. Despite these options, almost all patients will relapse post first-line autologous stem cell transplantation (ASCT). First relapse management (second-line treatment) has evolved in recent years with an expanding portfolio of novel agents, driving response rates influencing the durability of response. A second ASCT, as part of relapsed disease management (salvage ASCT), has been shown to prolong the progression-free survival and overall survival following a proteasome inhibitor-containing re-induction regimen, in the Cancer Research UK-funded National Cancer Research Institute Myeloma X (Intensive) study. It is now recommended that salvage ASCT be considered for suitable patients by the International Myeloma Working Group and the National Institute for Health and Care Excellence NG35 guidance.\nMETHODS/DESIGN: ACCoRd (Myeloma XII) is a UK-nationwide, individually randomised, multi-centre, multiple randomisation, open-label phase III trial with an initial single intervention registration phase aimed at relapsing MM patients who have received ASCT in first-line treatment. We will register 406 participants into the trial to allow 284 and 248 participants to be randomised at the first and second randomisations, respectively. All participants will receive re-induction therapy until maximal response (four to six cycles of ixazomib, thalidomide and dexamethasone). Participants who achieve at least stable disease will be randomised (1:1) to receive either ASCTCon, using high-dose melphalan, or ASCTAug, using high-dose melphalan with ixazomib. All participants achieving or maintaining a minimal response or better, following salvage ASCT, will undergo a second randomisation (1:1) to consolidation and maintenance or observation. Participants randomised to consolidation and maintenance will receive consolidation with two cycles of ixazomib, thalidomide and dexamethasone, and maintenance with ixazomib until disease progression.\nDISCUSSION: The question of how best to maximise the durability of response to salvage ASCT warrants clinical investigation. Given the expanding scope of oral therapeutic agents, patient engagement with long-term maintenance strategies is a real opportunity. This study will provide evidence to better define post-relapse treatment in MM.\nTRIAL REGISTRATION: ISRCTN, ISRCTN10038996 . Registered on 15 December 2016.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13063-018-2524-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5137201", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial", 
    "pagination": "169", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a4faaa3d8632ea1ea2f02563a398e3f09450b0658686556dbd96deb7a965dba5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29514706"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101263253"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-018-2524-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101375562"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-018-2524-8", 
      "https://app.dimensions.ai/details/publication/pub.1101375562"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000358_0000000358/records_127456_00000010.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13063-018-2524-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2524-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2524-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2524-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2524-8'


 

This table displays all metadata directly associated to this object as RDF triples.

370 TRIPLES      21 PREDICATES      77 URIs      45 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-018-2524-8 schema:about N03e423b1586a4c8e9c3cd1fbe0a6d365
2 N0e728bae839b407095963cc38c221335
3 N18c2e374d0314e2ba511c127a2defa1c
4 N2ee86a1480144b56b97ec11a9f010004
5 N34557a4d5ff64099840a2f41d8954e6c
6 N39a2f4ae6b114ca8aa4f2dd68b2f9f37
7 N3f3e350dae3c4e2abd52a1d549506ba7
8 N3f643474b1ce48eda6f818572ea1092e
9 N55425d14c9944166930304ef184db71a
10 N5c8da4a270c44dd383027ae94ae9bdad
11 N6755d76ff4164ebeb31e54bc339fa014
12 N6ebe1a3210704cc49777e5d5bf6cdd00
13 N7ee55600706e4074b06c5777d2a37e04
14 N85dd84073a95456789145ffafcf277d8
15 N96dd65f8361f4806b19f4a2ba1228cdd
16 Na342d66d209c46e4a5515d298751ea07
17 Nbe3df640b0a947aea7fe446732ad437b
18 Nd11394e8e4d64cdfb10e2f7e560bed11
19 Nd2997c06851e4aec826f71d49d1271e9
20 Ndf8b519880384c7483fe718943d8a602
21 Ne225ffefa2fb429c86b0a8823dda066f
22 Ne7d0356037f04b14aa7cc9464995ea42
23 Nf1d2ecddc76b4a2582c0b731a6c167ff
24 Nfc9465ff2c5147c79a29d41d6d2bef29
25 anzsrc-for:11
26 anzsrc-for:1112
27 schema:author Nb501c665a5be4997b180f2449a888c09
28 schema:citation sg:pub.10.1038/bcj.2014.71
29 sg:pub.10.1038/bmt.2015.175
30 sg:pub.10.1038/bmt.2015.83
31 sg:pub.10.1038/leu.2013.335
32 sg:pub.10.1038/leu.2015.356
33 https://doi.org/10.1002/sim.4780110205
34 https://doi.org/10.1016/j.leukres.2007.11.015
35 https://doi.org/10.1016/s1470-2045(14)70245-1
36 https://doi.org/10.1016/s1470-2045(14)71125-8
37 https://doi.org/10.1016/s2352-3026(16)30049-7
38 https://doi.org/10.1056/nejmoa022340
39 https://doi.org/10.1056/nejmoa1516282
40 https://doi.org/10.1111/bjh.12513
41 https://doi.org/10.1177/1740774510369019
42 https://doi.org/10.1182/blood-2002-06-1768
43 https://doi.org/10.1182/blood-2009-06-229658
44 https://doi.org/10.1182/blood-2011-02-338665
45 https://doi.org/10.1182/blood-2014-01-548826
46 https://doi.org/10.1200/jco.2011.39.6820
47 https://doi.org/10.1200/jco.2015.61.2267
48 https://doi.org/10.2147/ott.s49187
49 https://doi.org/10.2307/2530245
50 https://doi.org/10.2307/2988298
51 https://doi.org/10.3109/10428194.2012.746682
52 schema:datePublished 2018-12
53 schema:datePublishedReg 2018-12-01
54 schema:description BACKGROUND: Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors and immunomodulatory drugs. Despite these options, almost all patients will relapse post first-line autologous stem cell transplantation (ASCT). First relapse management (second-line treatment) has evolved in recent years with an expanding portfolio of novel agents, driving response rates influencing the durability of response. A second ASCT, as part of relapsed disease management (salvage ASCT), has been shown to prolong the progression-free survival and overall survival following a proteasome inhibitor-containing re-induction regimen, in the Cancer Research UK-funded National Cancer Research Institute Myeloma X (Intensive) study. It is now recommended that salvage ASCT be considered for suitable patients by the International Myeloma Working Group and the National Institute for Health and Care Excellence NG35 guidance. METHODS/DESIGN: ACCoRd (Myeloma XII) is a UK-nationwide, individually randomised, multi-centre, multiple randomisation, open-label phase III trial with an initial single intervention registration phase aimed at relapsing MM patients who have received ASCT in first-line treatment. We will register 406 participants into the trial to allow 284 and 248 participants to be randomised at the first and second randomisations, respectively. All participants will receive re-induction therapy until maximal response (four to six cycles of ixazomib, thalidomide and dexamethasone). Participants who achieve at least stable disease will be randomised (1:1) to receive either ASCTCon, using high-dose melphalan, or ASCTAug, using high-dose melphalan with ixazomib. All participants achieving or maintaining a minimal response or better, following salvage ASCT, will undergo a second randomisation (1:1) to consolidation and maintenance or observation. Participants randomised to consolidation and maintenance will receive consolidation with two cycles of ixazomib, thalidomide and dexamethasone, and maintenance with ixazomib until disease progression. DISCUSSION: The question of how best to maximise the durability of response to salvage ASCT warrants clinical investigation. Given the expanding scope of oral therapeutic agents, patient engagement with long-term maintenance strategies is a real opportunity. This study will provide evidence to better define post-relapse treatment in MM. TRIAL REGISTRATION: ISRCTN, ISRCTN10038996 . Registered on 15 December 2016.
55 schema:genre research_article
56 schema:inLanguage en
57 schema:isAccessibleForFree true
58 schema:isPartOf N7b808b333b7942b78ce6a09ea2a09865
59 Nc4606d9f78294999ae8fa813282296b4
60 sg:journal.1297400
61 schema:name The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
62 schema:pagination 169
63 schema:productId N44c889cd5b174de885b8a1e8c9b71121
64 N8163fa796afd492c9ad95d3491c51592
65 N92ddf1a93a6d4151b4b1ff5ba79e4901
66 Nc6afc6f2549147439c3deb262793339f
67 Ne0b6dde3ee7a4e6b9fd1446bcaa6e117
68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101375562
69 https://doi.org/10.1186/s13063-018-2524-8
70 schema:sdDatePublished 2019-04-11T11:45
71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
72 schema:sdPublisher Nba9ff10785464795848d0ca5e3a74eb2
73 schema:url https://link.springer.com/10.1186%2Fs13063-018-2524-8
74 sgo:license sg:explorer/license/
75 sgo:sdDataset articles
76 rdf:type schema:ScholarlyArticle
77 N03e423b1586a4c8e9c3cd1fbe0a6d365 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Progression-Free Survival
79 rdf:type schema:DefinedTerm
80 N0e728bae839b407095963cc38c221335 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Drug Administration Schedule
82 rdf:type schema:DefinedTerm
83 N18c2e374d0314e2ba511c127a2defa1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Stem Cell Transplantation
85 rdf:type schema:DefinedTerm
86 N2ee86a1480144b56b97ec11a9f010004 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Glycine
88 rdf:type schema:DefinedTerm
89 N34557a4d5ff64099840a2f41d8954e6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Multiple Myeloma
91 rdf:type schema:DefinedTerm
92 N39a2f4ae6b114ca8aa4f2dd68b2f9f37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Neoplasm, Residual
94 rdf:type schema:DefinedTerm
95 N3ac32238ad5c46e097c8e6d0019f3577 rdf:first sg:person.01344072571.30
96 rdf:rest Nd1d42bb94b224b0cb778934073d23980
97 N3f3e350dae3c4e2abd52a1d549506ba7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Proteasome Inhibitors
99 rdf:type schema:DefinedTerm
100 N3f643474b1ce48eda6f818572ea1092e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Maintenance Chemotherapy
102 rdf:type schema:DefinedTerm
103 N44c889cd5b174de885b8a1e8c9b71121 schema:name readcube_id
104 schema:value a4faaa3d8632ea1ea2f02563a398e3f09450b0658686556dbd96deb7a965dba5
105 rdf:type schema:PropertyValue
106 N477966d00ae74b30929b0efd18de4876 rdf:first sg:person.07771451501.02
107 rdf:rest Nf43cbbf2dfb849eb940427e308443a52
108 N4ca1bae5994d414286dcebb09e099830 rdf:first sg:person.0764445325.21
109 rdf:rest N85c4bf8bd8114ec0b2addebc4ce0706e
110 N55425d14c9944166930304ef184db71a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Recurrence
112 rdf:type schema:DefinedTerm
113 N5c8da4a270c44dd383027ae94ae9bdad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Salvage Therapy
115 rdf:type schema:DefinedTerm
116 N65ef6acc277a48b0b026d92b9f24a78f rdf:first sg:person.013760076760.23
117 rdf:rest Necf83c33b46a4238a6a04708c4fe9512
118 N6755d76ff4164ebeb31e54bc339fa014 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Male
120 rdf:type schema:DefinedTerm
121 N6ebe1a3210704cc49777e5d5bf6cdd00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Boron Compounds
123 rdf:type schema:DefinedTerm
124 N7b808b333b7942b78ce6a09ea2a09865 schema:issueNumber 1
125 rdf:type schema:PublicationIssue
126 N7ee55600706e4074b06c5777d2a37e04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Humans
128 rdf:type schema:DefinedTerm
129 N80723523077d4c07a7fa4d0defa65bb0 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
130 schema:familyName Boardman
131 schema:givenName Karen
132 rdf:type schema:Person
133 N8163fa796afd492c9ad95d3491c51592 schema:name pubmed_id
134 schema:value 29514706
135 rdf:type schema:PropertyValue
136 N82b3ed3a4df943408346b64d51af2ad9 rdf:first sg:person.01157221563.81
137 rdf:rest N3ac32238ad5c46e097c8e6d0019f3577
138 N85c4bf8bd8114ec0b2addebc4ce0706e rdf:first sg:person.0751765342.08
139 rdf:rest Nbc3face31ca44783a7dd26faf43c233f
140 N85dd84073a95456789145ffafcf277d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Transplantation, Autologous
142 rdf:type schema:DefinedTerm
143 N92ddf1a93a6d4151b4b1ff5ba79e4901 schema:name doi
144 schema:value 10.1186/s13063-018-2524-8
145 rdf:type schema:PropertyValue
146 N96dd65f8361f4806b19f4a2ba1228cdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Randomized Controlled Trials as Topic
148 rdf:type schema:DefinedTerm
149 Na28d075b1dff4220af52f2b0b037a8da schema:name Leeds Institute of Cancer & Pathology, University of Leeds, St James’s University Hospital, Leeds, UK
150 rdf:type schema:Organization
151 Na342d66d209c46e4a5515d298751ea07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Treatment Outcome
153 rdf:type schema:DefinedTerm
154 Na53f320240af4560bab82c557cf983c7 rdf:first N80723523077d4c07a7fa4d0defa65bb0
155 rdf:rest N65ef6acc277a48b0b026d92b9f24a78f
156 Nb316921bbf0e402fb4b2c34fd31ae7a4 rdf:first sg:person.0675442301.72
157 rdf:rest N477966d00ae74b30929b0efd18de4876
158 Nb501c665a5be4997b180f2449a888c09 rdf:first sg:person.015350452375.41
159 rdf:rest Nb316921bbf0e402fb4b2c34fd31ae7a4
160 Nba9ff10785464795848d0ca5e3a74eb2 schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 Nbc3face31ca44783a7dd26faf43c233f rdf:first sg:person.0707335607.63
163 rdf:rest Ne4f41220c5774b75be82671fe5c2d841
164 Nbe3df640b0a947aea7fe446732ad437b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Female
166 rdf:type schema:DefinedTerm
167 Nc4606d9f78294999ae8fa813282296b4 schema:volumeNumber 19
168 rdf:type schema:PublicationVolume
169 Nc6afc6f2549147439c3deb262793339f schema:name dimensions_id
170 schema:value pub.1101375562
171 rdf:type schema:PropertyValue
172 Nd11394e8e4d64cdfb10e2f7e560bed11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Quality of Life
174 rdf:type schema:DefinedTerm
175 Nd1d42bb94b224b0cb778934073d23980 rdf:first sg:person.07624006200.62
176 rdf:rest rdf:nil
177 Nd2997c06851e4aec826f71d49d1271e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Transplantation Conditioning
179 rdf:type schema:DefinedTerm
180 Ndf8b519880384c7483fe718943d8a602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Multicenter Studies as Topic
182 rdf:type schema:DefinedTerm
183 Ne0b6dde3ee7a4e6b9fd1446bcaa6e117 schema:name nlm_unique_id
184 schema:value 101263253
185 rdf:type schema:PropertyValue
186 Ne225ffefa2fb429c86b0a8823dda066f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Clinical Trials, Phase III as Topic
188 rdf:type schema:DefinedTerm
189 Ne4f41220c5774b75be82671fe5c2d841 rdf:first sg:person.01164220446.81
190 rdf:rest N82b3ed3a4df943408346b64d51af2ad9
191 Ne7d0356037f04b14aa7cc9464995ea42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Antineoplastic Agents
193 rdf:type schema:DefinedTerm
194 Necf83c33b46a4238a6a04708c4fe9512 rdf:first sg:person.016555374462.34
195 rdf:rest Nfa4b99500e204f89bf2762e0fcc4e7ad
196 Nf1d2ecddc76b4a2582c0b731a6c167ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name United Kingdom
198 rdf:type schema:DefinedTerm
199 Nf43cbbf2dfb849eb940427e308443a52 rdf:first sg:person.01100525223.10
200 rdf:rest Na53f320240af4560bab82c557cf983c7
201 Nfa4b99500e204f89bf2762e0fcc4e7ad rdf:first sg:person.012030144222.63
202 rdf:rest N4ca1bae5994d414286dcebb09e099830
203 Nfc9465ff2c5147c79a29d41d6d2bef29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Time Factors
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
210 schema:name Oncology and Carcinogenesis
211 rdf:type schema:DefinedTerm
212 sg:grant.5137201 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2524-8
213 rdf:type schema:MonetaryGrant
214 sg:journal.1297400 schema:issn 1468-6708
215 1745-6215
216 schema:name Trials
217 rdf:type schema:Periodical
218 sg:person.01100525223.10 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
219 schema:familyName Cairns
220 schema:givenName David A.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100525223.10
222 rdf:type schema:Person
223 sg:person.01157221563.81 schema:affiliation https://www.grid.ac/institutes/grid.443984.6
224 schema:familyName Owen
225 schema:givenName Roger
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157221563.81
227 rdf:type schema:Person
228 sg:person.01164220446.81 schema:affiliation https://www.grid.ac/institutes/grid.6572.6
229 schema:familyName Drayson
230 schema:givenName Mark T.
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164220446.81
232 rdf:type schema:Person
233 sg:person.012030144222.63 schema:affiliation https://www.grid.ac/institutes/grid.31410.37
234 schema:familyName Snowden
235 schema:givenName John A.
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012030144222.63
237 rdf:type schema:Person
238 sg:person.01344072571.30 schema:affiliation https://www.grid.ac/institutes/grid.415490.d
239 schema:familyName Cook
240 schema:givenName Mark
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344072571.30
242 rdf:type schema:Person
243 sg:person.013760076760.23 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
244 schema:familyName Jacques
245 schema:givenName Gwen
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013760076760.23
247 rdf:type schema:Person
248 sg:person.015350452375.41 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
249 schema:familyName Striha
250 schema:givenName Alina
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015350452375.41
252 rdf:type schema:Person
253 sg:person.016555374462.34 schema:affiliation https://www.grid.ac/institutes/grid.240404.6
254 schema:familyName Williams
255 schema:givenName Cathy
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016555374462.34
257 rdf:type schema:Person
258 sg:person.0675442301.72 schema:affiliation https://www.grid.ac/institutes/grid.415005.5
259 schema:familyName Ashcroft
260 schema:givenName A. John
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675442301.72
262 rdf:type schema:Person
263 sg:person.0707335607.63 schema:affiliation https://www.grid.ac/institutes/grid.439749.4
264 schema:familyName Yong
265 schema:givenName Kwee
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707335607.63
267 rdf:type schema:Person
268 sg:person.0751765342.08 schema:affiliation https://www.grid.ac/institutes/grid.416353.6
269 schema:familyName Cavenagh
270 schema:givenName Jamie
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751765342.08
272 rdf:type schema:Person
273 sg:person.07624006200.62 schema:affiliation Na28d075b1dff4220af52f2b0b037a8da
274 schema:familyName Cook
275 schema:givenName Gordon
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07624006200.62
277 rdf:type schema:Person
278 sg:person.0764445325.21 schema:affiliation https://www.grid.ac/institutes/grid.419248.2
279 schema:familyName Garg
280 schema:givenName Mamta
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764445325.21
282 rdf:type schema:Person
283 sg:person.07771451501.02 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
284 schema:familyName Hockaday
285 schema:givenName Anna
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07771451501.02
287 rdf:type schema:Person
288 sg:pub.10.1038/bcj.2014.71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013760776
289 https://doi.org/10.1038/bcj.2014.71
290 rdf:type schema:CreativeWork
291 sg:pub.10.1038/bmt.2015.175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035017085
292 https://doi.org/10.1038/bmt.2015.175
293 rdf:type schema:CreativeWork
294 sg:pub.10.1038/bmt.2015.83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007789680
295 https://doi.org/10.1038/bmt.2015.83
296 rdf:type schema:CreativeWork
297 sg:pub.10.1038/leu.2013.335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011949021
298 https://doi.org/10.1038/leu.2013.335
299 rdf:type schema:CreativeWork
300 sg:pub.10.1038/leu.2015.356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035584393
301 https://doi.org/10.1038/leu.2015.356
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1002/sim.4780110205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012639418
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1016/j.leukres.2007.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033675460
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1016/s1470-2045(14)70245-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050595830
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1016/s1470-2045(14)71125-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012022447
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1016/s2352-3026(16)30049-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051977126
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1056/nejmoa022340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043734366
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1056/nejmoa1516282 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035239228
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1111/bjh.12513 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016883864
318 rdf:type schema:CreativeWork
319 https://doi.org/10.1177/1740774510369019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011719554
320 rdf:type schema:CreativeWork
321 https://doi.org/10.1182/blood-2002-06-1768 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049049948
322 rdf:type schema:CreativeWork
323 https://doi.org/10.1182/blood-2009-06-229658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048946419
324 rdf:type schema:CreativeWork
325 https://doi.org/10.1182/blood-2011-02-338665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042868402
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1182/blood-2014-01-548826 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039247879
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1200/jco.2011.39.6820 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029641259
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1200/jco.2015.61.2267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038717218
332 rdf:type schema:CreativeWork
333 https://doi.org/10.2147/ott.s49187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011617405
334 rdf:type schema:CreativeWork
335 https://doi.org/10.2307/2530245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069975779
336 rdf:type schema:CreativeWork
337 https://doi.org/10.2307/2988298 schema:sameAs https://app.dimensions.ai/details/publication/pub.1102979429
338 rdf:type schema:CreativeWork
339 https://doi.org/10.3109/10428194.2012.746682 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015826881
340 rdf:type schema:CreativeWork
341 https://www.grid.ac/institutes/grid.240404.6 schema:alternateName Nottingham University Hospitals NHS Trust
342 schema:name Centre for Clinical Haematology, Nottingham University Hospitals (City Campus), Nottingham, UK
343 rdf:type schema:Organization
344 https://www.grid.ac/institutes/grid.31410.37 schema:alternateName Sheffield Teaching Hospitals NHS Foundation Trust
345 schema:name Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
346 rdf:type schema:Organization
347 https://www.grid.ac/institutes/grid.415005.5 schema:alternateName Pinderfields Hospital
348 schema:name Department of Haematology, Pinderfields General Hospital, Wakefield, UK
349 rdf:type schema:Organization
350 https://www.grid.ac/institutes/grid.415490.d schema:alternateName Queen Elizabeth Hospital Birmingham
351 schema:name Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham, UK
352 rdf:type schema:Organization
353 https://www.grid.ac/institutes/grid.416353.6 schema:alternateName St Bartholomew's Hospital
354 schema:name Department of Haematology, St Bartholomew’s Hospital, London, UK
355 rdf:type schema:Organization
356 https://www.grid.ac/institutes/grid.419248.2 schema:alternateName Leicester Royal Infirmary
357 schema:name Leicester Royal Infirmary, Leicester, UK
358 rdf:type schema:Organization
359 https://www.grid.ac/institutes/grid.439749.4 schema:alternateName University College Hospital
360 schema:name Department of Haematology, University College Hospital, London, UK
361 rdf:type schema:Organization
362 https://www.grid.ac/institutes/grid.443984.6 schema:alternateName St James's University Hospital
363 schema:name HMDS, St James’s University Hospital, Leeds, UK
364 rdf:type schema:Organization
365 https://www.grid.ac/institutes/grid.6572.6 schema:alternateName University of Birmingham
366 schema:name Myeloma Clinical Trials Unit, University of Birmingham, Birmingham, UK
367 rdf:type schema:Organization
368 https://www.grid.ac/institutes/grid.9909.9 schema:alternateName University of Leeds
369 schema:name Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
370 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...